1-5 of 5
Nitya Nair
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying Chen, Jincheng Wu, Thomas W. Dubensky, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Jason J. Luke
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2336.
https://doi.org/10.1158/1078-0432.CCR-23-1170
Published: 13 June 2023
View article titled, Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Open the PDF for Correction: Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas in another window
Journal Articles

Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study

Funda Meric-Bernstam, Randy F. Sweis, Stefan Kasper, Omid Hamid, Shailender Bhatia, Reinhard Dummer, Agostina Stradella, Georgina V. Long, Anna Spreafico, Toshio Shimizu, Neeltje Steeghs, Jason J. Luke, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Nancy Lewis, Xinhui Chen, Andrew Bean, Lisa Kattenhorn, Marc Pelletier, Shahneen Sandhu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 110–121.
https://doi.org/10.1158/1078-0432.CCR-22-2235
Published: 04 January 2023
View article titled, Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Open the PDF for Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

Funda Meric-Bernstam, Randy F. Sweis, F. Stephen Hodi, Wells A. Messersmith, Robert H.I. Andtbacka, Matthew Ingham, Nancy Lewis, Xinhui Chen, Marc Pelletier, Xueying Chen, Jincheng Wu, Thomas W. Dubensky, Sarah M. McWhirter, Thomas Müller, Nitya Nair, Jason J. Luke
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 677–688.
https://doi.org/10.1158/1078-0432.CCR-21-1963
Published: 15 February 2022
View article titled, Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Open the PDF for Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas in another window
Includes: Supplementary data
Journal Articles

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma

Raffit Hassan, Evan Alley, Hedy Kindler, Scott Antonia, Thierry Jahan, Somayeh Honarmand, Nitya Nair, Chan C. Whiting, Amanda Enstrom, Ed Lemmens, Takahiro Tsujikawa, Sushil Kumar, Gina Choe, Anish Thomas, Katherine McDougall, Aimee L. Murphy, Elizabeth Jaffee, Lisa M. Coussens, Dirk G. Brockstedt
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (19): 5787–5798.
https://doi.org/10.1158/1078-0432.CCR-19-0070
Published: 01 October 2019
View article titled, Clinical Response of Live-Attenuated, <em>Listeria monocytogenes</em> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma
Open the PDF for Clinical Response of Live-Attenuated, <em>Listeria monocytogenes</em> Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma in another window
Includes: Supplementary data
Journal Articles

Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)

Dung T. Le, Vincent J. Picozzi, Andrew H. Ko, Zev A. Wainberg, Hedy Kindler, Andrea Wang-Gillam, Paul Oberstein, Michael A. Morse, Herbert J. Zeh, III, Colin Weekes, Tony Reid, Erkut Borazanci, Todd Crocenzi, Noelle K. LoConte, Benjamin Musher, Dan Laheru, Aimee Murphy, Chan Whiting, Nitya Nair, Amanda Enstrom, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5493–5502.
https://doi.org/10.1158/1078-0432.CCR-18-2992
Published: 13 September 2019
View article titled, Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study)
Open the PDF for Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pancreatic Adenocarcinoma (ECLIPSE Study) in another window
Includes: Supplementary data